TIA enables access to expertise relevant to multiple therapeutic modalities. Each area is supported by a dedicated broker/facilitator with expertise in therapeutic development who can help you get the support you need.
Click on the boxes below to highlight capabilities for each therapeutic, and click on reset to show all.
TIA’s small molecule drug development pathway is supported by industry-standard and cost-effective compound library management and logistics to support high throughput screening. Compound libraries available in assay-ready formats include open access collections (drug libraries, academic library, scaffolds library), closed access collections (proprietary collections) and specialised collections (NatureBank and Australian Lead Identification Consortium).
High throughput screening
Rapid, large-scale testing of large compound libraries to identify novel compounds
TIA enables access to a network of advanced high and ultra-high throughput screening centres across the country, including a broad range of assay technology and supporting expertise. Libraries of up to 300,000 novel compounds can be screened in a few days, and identified hit compounds can be rapidly identified for further investigation.
Medicinal chemistry and lead optimisation
ADME-guided development and synthesis of novel small molecule therapeutics
TIA’s facilities offer specialised multi-disciplinary services in early-phase drug discovery and development, incorporating medicinal chemistry and ADME-guided lead optimisation to multidisciplinary drug discovery teams for improved compound design, selection and progression. Services include medicinal and synthetic chemistry, hit-to-lead activities, structure-activity relationship probing, physicochemical profiling, drug metabolism, in vitro biopharmaceutics, in vivo pharmacokinetics and bioanalysis using LC-MS/MS.
Preclinical efficacy testing
Testing of therapeutics in disease models in preparation for clinical trials
TIA offers access to advanced preclinical disease models in NATA-accredited facilities. With a particular expertise and experience in the field of pain, the services can be used to screen new molecules for analgesic activity and to probe the pathobiology of individual human pain conditions. The accredited mature of the facilities means that the resulting data is investor- and regulator-ready.
Development, manufacturing and regulatory advice
Advice to help you translate your research discovery into a potential medical product
Developing novel therapeutic products is risky, expensive and takes a long time. TIA facilities can help you understand the many steps involved in developing your product, reducing risk and improving the pathway to commercialisation.
Having lived experience of navigating regulatory pathways, and working with industry partners, TIA facility staff are a great resource to help you understand the necessary steps towards starting a clinical trial and making complex regulatory submissions.
Establishing quality systems
A library of documents to help you develop an in-house quality system
A fit-for-purpose quality system is crucial to ensure reliability and reproducibility of results, and is a prerequisite for accreditation under many internationally-recognised codes of practice. When setting up a quality system for the first time, TIA has brought together a suite of documents, named iQDOCs, with generic examples of documents relevant for each of the common standards, from ISO9001 to FACT and TGA-licenced GMP. Our facilities work within phase-appropriate quality frameworks relevant for their needs and these documents can also assist in establishing, maintaining or build your quality system.